Literature DB >> 1394445

Effect of immunosuppressive therapy on cytolytic activity of immunodeficient mice: implications for xenogeneic transplantation.

L A Cavacini1, J Giles-Komar, M Kennel, A Quinn.   

Abstract

Despite major deficits in their immune system, SCID, Nude, and NIH III mice reject allo- and xenografts, particularly leukemic cell lines, albeit less readily than immunologically intact mice. Since variation among these immunodeficient mouse strains in rejection of a human lymphoid cell line (CCRF-CEM) parallels splenic non-MHC-mediated cytolytic activity, non-MHC-restricted cytolytic activity may be responsible for retained resistance to leukemic cell transplantation. SCID mice that had the least cytolytic activity accepted 100% of their grafts. The converse was true for NIH III mice that showed the greatest cytolytic activity and were relatively resistant to CEM cell engraftment. Different approaches to ablate NK activity and thus enhance engraftment led to variable results for each strain. A single dose (500 micrograms) of anti-asialoGM1 (AsGM1) markedly reduced NK activity in SCID and NIH III mice by 60 and 40%, respectively. A moderate 20% decrease was seen in Nude mice at this dose. In contrast, gamma irradiation suppressed NK activity by greater than 80% of baseline levels in all three strains. Of importance, total cytolytic activity in immunosuppressed Nude and NIH III mice, although significantly depressed compared to untreated mice of the same strain, still remained higher than that seen in nonimmunosuppressed SCID mice. Enhanced engraftment and systemic dissemination of CEM cells in immunosuppressed mice correlated directly with decreased total splenic cytolytic activity in all three strains. These results have implications for the use of immunodeficient models for transplantation, tumor immunobiology, and engraftment of a human immune system.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1394445     DOI: 10.1016/0008-8749(92)90246-l

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  5 in total

1.  Irradiated compared with nonirradiated NSG mice for the development of a human B-cell lymphoma model.

Authors:  Deepti Chadalavada; Trinka W Adamson; John C Burnett; Robert W Chen; John J Rossi
Journal:  Comp Med       Date:  2014-06       Impact factor: 0.982

2.  Inhibitory effects of bovine lactoferrin on colon carcinoma 26 lung metastasis in mice.

Authors:  M Iigo; T Kuhara; Y Ushida; K Sekine; M A Moore; H Tsuda
Journal:  Clin Exp Metastasis       Date:  1999-02       Impact factor: 5.150

3.  Potential role of natural killer cells in controlling tumorigenesis by human T-cell leukemia viruses.

Authors:  G Feuer; S A Stewart; S M Baird; F Lee; R Feuer; I S Chen
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

4.  Targeted Cancer Therapy with a Novel Anti-CD37 Beta-Particle Emitting Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma.

Authors:  Ada H V Repetto-Llamazares; Roy H Larsen; Sebastian Patzke; Karianne G Fleten; David Didierlaurent; Alexandre Pichard; Jean Pierre Pouget; Jostein Dahle
Journal:  PLoS One       Date:  2015-06-11       Impact factor: 3.240

5.  The structure of SeviL, a GM1b/asialo-GM1 binding R-type lectin from the mussel Mytilisepta virgata.

Authors:  Kenichi Kamata; Kenji Mizutani; Katsuya Takahashi; Roberta Marchetti; Alba Silipo; Christine Addy; Sam-Yong Park; Yuki Fujii; Hideaki Fujita; Tsuyoshi Konuma; Takahisa Ikegami; Yasuhiro Ozeki; Jeremy R H Tame
Journal:  Sci Rep       Date:  2020-12-16       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.